secwatch.observer — SEC 8-K summary
======================================

Issuer:     CymaBay Therapeutics, Inc. (—)
CIK:        0001042074
Form:       8-K
Filed at:   2024-01-26T23:59:59+00:00
Accession:  0001193125-24-016706
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CymaBay appoints Harish Shantharam as principal accounting officer; updates director comp
--------------------------------------------------------------------------------

- Daniel Menold ceased as principal accounting officer on Jan 24, 2024, remains an employee.
- Harish Shantharam (CFO) named principal accounting officer, in addition to his CFO role.
- Non-Employee Director Compensation amended: annual equity award valued at ~$250k; initial award ~$400k.
- Cash retainers unchanged: $40k annual base, $30k board chair, audit chair $20k, comp chair $15k, nominating chair $10k.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1042074/000119312524016706/0001193125-24-016706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1042074/000119312524016706/d687696d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-016706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer